Influenza and Respiratory Viruses Department projects	
No	project
1	Construction of a chimerical expression vector carrying influenza virus M2 protein and HSP70 gene and protein expression in COS-7 and/or HEK 293 cells
2	Application of Multiplex Real Time PCR in order to detect respiratory viruses in clinical samples collected from acute respiratory infected patients
3	Evaluating hemagglutinin and neuraminidase genetic changes in recent H1N1 influenza viruses in comparison with 2009 pandemic vaccine strain
4	Investigation on Coronavirus shedding duration among COVID-19 infected individuals
5	Evaluation of viral infections in patients with respiratory symptoms and negative result of COVID-19
6 (241)	Suspending MDCK cell line for large scale culture of influenza virus
7 (252)	Production of M2-HSP70 chimeric protein containing influenza virus M2 protein and Leishmania Major HSP70 in prokaryotic system (E.coli) and assessment of its immunogenicity in mice
8 (421)	Reconstituting a recombinant chimeric influenza virosome associated with VSV as a delivery system for insect and mammalian cell lines
9 (439)	Prokaryotic production and protectivity assessment of chimer Protein consisting of Influenza Virus conserved Domains of Hemagglutinin , Matrix protein (3M2e-HA2) and Nucleoprotein (NP) in mouse model
10 (622)	Production and protectivity assessment of intranasal administration of polyclonal antibodies against whole Influenza A/H1N1virus and conserved proteins (HA2& M2) in mice
11 (1309)	Expression of Human Influenza Hemagglutinin in BES (Baculovirus Expression System
12 (1371)	Evaluation of the susceptibility to influenza virus in people suffering from Hypercholesterolemia and diabetes in terms of IFITM3 polymorphism rs12252-C
13 (1520)	Expression of Hemagglutinin (HA) proteins in Tobacco plant for production of virus-like particles as vaccine candidate
14 (1524)	Evaluation of the neutralizing activity of antibodies induced by H5 influenza vaccines through production of lentiviral pseudovirus particle
15 (1807)	Design, Cloning and expression of chimeric protein composed of the antigenic regions of hemagglutinin and conserved domains of influenza virus in Nicotiana benthamiana and immunogenicity assessment in mouse model
16 (1808)	Design, synthesis and evaluation of protective effect of inhaled form of antiviral peptides against influenza A virus hemagglutinin in mouse model
17 (1880)	Association of the host genetic risk factors with influenza disease severity
18 (1939)	Application evaluation of gemini surfactants as antiviral and virucidal (antiseptic)
19 (1944)	Immunogenicity and protectivity evaluation of vaccine candidate constructs consist of immunodominant epitopes of influenza virus surface proteins (hemagglutinin and neuraminidase) in prokaryotic system
20 (2012)	Evaluation of Covaxin Baharat India vaccine in symptomatic and asymptomatic further infection and vaccine escape variants detection

21	Comparing the efficacy of Influenza virosomes with chimeric Influenza-VSV virosomes for delievery of DNA vaccine in tumor mice model
22	Evaluation of influenza virosome potency as carrier of plasmid expressing influenza M2 gene and GM-CSF as genetic adjuvant
23	Evaluation of combination of virosome containing conserved epitopes of influenza virus (prime) and gamma-inactivated influenza virus(boost) in inducing protective immune response in murine influenza model.
24	Comparing the efficacy of Influenza virosomes with chimeric Influenza-VSV virosomes for delievery of DNA vaccine in tumor mice model
25	Evaluation of influenza virosome potency as carrier of plasmid expressing influenza M2 gene and GM-CSF as genetic adjuvant
26 (1720)	Isolation, characterization and molecular docking of active compounds of Phlomis plant and the study of their antiviral effect against influenza virus
27	Comparison of influenza virus infectivity on 2D and 3D A549 and HEK293 cells
28	Isolation and characterization of respiratory viruses from nasopharyngeal specimen of patients with respiratory diseases to develop a virus bank
29 (2106)	Optimizing the expression of the active form of neuraminidase in bacterial host to facilitate pharmacological studies against influenza
30	Evaluation of combination therapy using Newcastle oncolytic virus along with Everolimus and Beclin, for tumor immunotherapy in TC-1-induced tumor in C57BL/ female mouse model.
31	Evaluation gamma inactivated influenza vaccine in inducing protective immune response by different adjuvant formulations for in murine influenza model.
32	Evaluation of the protective ability of using cell-penetrating peptides for the promotion of recombinant Influenza virus vaccine efficacy
33 (496)	The Isolation and characterization of Recombinant Camelids' Nanobody Against G glycoprotein of Rabies Virus

34	Prokaryotic expression of the respiratory syncytial virus F protein conserved domain, and evaluation of its immunogenicity and protectivity in a mouse model for vaccine development
35 (1260)	synthesis and Lab scale production of Sucrose monolaurate Sugar surfactant inorder to biodegradable compounds generation (such as detergent, adjuvant, drug delivery system and …)
36 (1327)	Virosome construction from Influenza virus to include Nucleoprotein gene as DNA Vaccine against the virus
37 (1360)	Application of avian Newcastle disease virus (NDV) in combination with influenza hemaglutinin Fusogenic membrane glycoproteins (FMGs) gene as novel therapy for murine model of human papillomavirus –induced cancer
38 (1370)	Evaluation of protective and anti-influenza immunity of influenza virosome potency as carrier of plasmid expressing influenza M2 gene and GM-CSF as genetic adjuvant in BALB/c mice model
39 (1461)	Surveying of PF-573,228 effects on interaction of rabies virus P protein and FAK
40 (1823)	Evaluation gamma inactivated influenza vaccine in inducing protective immune response by different adjuvant formulations for in murine influenza model
41 (1842)	Study of serum Zn and Se levels and metabonomics of the serum of patients of Covid19 using 1HNMR spectroscopy
42 (1893)	Long term clinical and serological assessment of confirmed COVID-19 infected individuals for finding re-infection cases during 1 year after onset of infection
43 (2060)	Immunogenicity and safety evaluation of PastoCovac Plus as the booster dose in Iranian adults aged from 18 to 80 who received two doses of Sinofarm and Astrazeneca